Trump signs order to speed review of psychedelics, including the controversial drug ibogaine
Trump joined by Joe Rogan as he signs order to speed up psychedelic review
AI Summary
In April 2026, President Donald Trump signed an executive order directing his administration to expedite the review process for certain psychedelic drugs, including ibogaine. Ibogaine, derived from a West African shrub, has gained attention from veterans and lawmakers for its potential to treat conditions like PTSD and opioid addiction, despite safety concerns. While these drugs remain in the most restrictive category under federal law, the administration aims to ease restrictions and encourage research into their medical applications, such as severe depression. Trump stated the order would accelerate access to potential treatments, emphasizing the potential for significant impact if the drugs prove effective. The move follows pledges from administration officials to ease access to psychedelics for medical use, reflecting bipartisan support for the issue.
Article Analysis
Key Claims (4)
AI-ExtractedIbogaine and other psychedelics remain banned under the federal government’s most restrictive category for illegal, high-risk drugs.
President Trump directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine.
Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives.
Ibogaine has great promise for hard-to-treat conditions such as post-traumatic stress disorder and opioid addiction.
Key Entities & Roles
Keywords
Sentiment Analysis
Source Transparency
This article was automatically classified using rule-based analysis.
Topic Connections
Explore how the topics in this article connect to other news stories
Related Coverage (3)
Find Similar Articles
AI-PoweredDiscover articles with similar content using semantic similarity analysis.